Free Trial

Novartis (NVS) SEC Filings & 10K Form

Novartis logo
$132.50 +0.19 (+0.14%)
As of 11:50 AM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Recent Novartis SEC Filings

DateFilerForm TypeView
09/30/2025
4:12 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
09/29/2025
5:53 AM
Novartis (Filed by)
Tourmaline Bio, Inc. (Subject)
Tourmaline Bio, Inc. (Subject)
Form SC TO-T
07/17/2025
3:15 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
07/17/2025
6:16 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
06/25/2025
8:24 AM
Novartis (Filed by)
Regulus Therapeutics Inc. (Subject)
Form SC TO-T/A
06/23/2025
5:02 AM
Novartis (Filed by)
Regulus Therapeutics Inc. (Subject)
Form SC TO-T/A
06/17/2025
5:30 AM
Novartis (Filed by)
Regulus Therapeutics Inc. (Subject)
Form SC TO-T/A
06/02/2025
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
05/27/2025
5:56 AM
Novartis (Filed by)
Regulus Therapeutics Inc. (Subject)
Form SC TO-T
05/01/2025
4:00 PM
Novartis (Filed by)
Regulus Therapeutics Inc. (Subject)
Form SC TO-C
04/30/2025
4:00 PM
Novartis (Filed by)
Regulus Therapeutics Inc. (Subject)
Form SC TO-C
04/29/2025
5:01 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
04/02/2025
8:35 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
03/28/2025
1:01 PM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/31/2025
6:07 AM
Novartis (Filer)
Form 20-F
Registration statement / Annual report / Transition report  
01/31/2025
6:12 AM
Novartis (Filer)
Form IRANNOTICE
01/31/2025
6:14 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
01/31/2025
6:16 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
12/30/2024
5:05 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
11/25/2024
9:20 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
10/29/2024
5:20 AM
Novartis (Filer)
Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934  
(Data available from 1/1/2016 forward)


Related Companies and Tools


This page (NYSE:NVS) was last updated on 10/9/2025 by MarketBeat.com Staff
From Our Partners